Given the current lack of clinical data assessing the employment of circulating PCSK9 as a prognostic biomarker in the context of breast neoplastic events, we conducted a prospective analysis within a randomized chemoprevention trial for premenopausal women at risk of breast cancer. Here, PCSK9 is linked to breast carcinoma.